相关实验视频

Updated: Jun 5, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

使用虚拟选,分子对接和动态模拟研究来探索潜在的GPR55激动剂

Vasavi Garisetti¹, Roslin Elsa Varughese¹, Arthikasree Anandamurthy¹

¹Centre of Advanced Study in Crystallography and Biophysics, University of Madras, Chennai, Tamil Nadu, India.

Journal of biomolecular structure & dynamics

|December 9, 2024

概括

研究人员确定了新型的 thiazole 和 triazole 化合物作为 G 蛋白结合受体 55 (GPR55) 的潜在激动剂,为神经系统疾病提供了新的治疗途径.

科学领域:

药用化学医学化学
神经药理学神经药理学
计算化学的计算化学

背景情况:

G蛋白结合受体55 (GPR55) 与神经系统疾病有关,因此其激活对于调节神经反应至关重要.
识别可以作为GPR55激动剂的特定配体对于开发向疗法的发展至关重要.

研究的目的:

以计算方式选和识别具有潜在GPR55激动剂活性的新型配体.
调查与GPR55受体识别的配体的结合相互作用和动态行为.

主要方法:

基于结构的ChemDiv数据库与预测的GPR55模型进行虚拟选.
进行了分子对接,分子动力学模拟,自由能量景观和MMPBSA分析.
提亚 (SVS1) 和三 (SVS2) 衍生物的合成和表征之前已经报告过.

主要成果:

虚拟选确定了 thiazole 和 triazole 衍生物作为最受欢迎的药物,其中两个化合物 (lead1 和 lead2) 进入了入围名单.
分子动力学模拟显示了1,2,SVS1,SVS2和GPR55受体之间的有希望的相互作用.
使用已知的激动剂 (O-1602) 的比较分析支持了这些已识别的化合物的潜力.

结论:

该研究强调了1,2,SVS1和SVS2作为GPR55激动剂的潜力.
thiazole 和 triazole 分组对于与 GPR55.5 的联结体相互作用至关重要.
这些发现为开发神经系统疾病的新疗法开辟了有希望的途径.

关键词:

在GPCR中,GPCR是指GPCR.在GPR55中,GPR55是最常见的.分子对接的分子对接.分子动力学模拟,分子动力学模拟虚拟选虚拟选虚拟选

更多相关视频

Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay

Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay

Published on: March 10, 2020

Strategic Screening and Characterization of the Visual GPCR-mini-G Protein Signaling Complex for Successful Crystallization

Strategic Screening and Characterization of the Visual GPCR-mini-G Protein Signaling Complex for Successful Crystallization

Published on: March 16, 2020

相关概念视频

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...